This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Marc O. Yoshizumi, MD
Los Angeles

Arch Ophthalmol. 1984;102(9):1268.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

In Reply.

—We agree with the findings of Leeds et al regarding the safe dose of intravitreal moxalactam. The importance of using moxalactam in a specific, localized intravitreal injection has been recently underscored by the reports of bleeding complications in some patients who have received systemic moxalactam.^1,2 Moxalactam and preprothrombin share a structural similarity. This structural similarity may cause inhibition of prothrombin formation. Another theory of moxalactam-related bleeding may be that the intestinal flora is destroyed by the antibiotic, resulting in a deficiency of vitamin K—dependent clotting factors. Moxalactam may further prolong bleeding time by interfering with platelet aggregation. We have not found hemorrhaging to be a problem when moxalactam was administered intravitreally. This is most probably due to the very small doses used in a localized area.

The advantage of moxalactam is its broad spectrum, which includes both staphylococci, as pointed out by Leeds et al, but, even . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?